- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
- Drug · Other
- Lead sponsor
- Kythera Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab, Matching placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12,537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Placebo, Venetoclax, Cytarabine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Louisville, Kentucky • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Asthma
- Interventions
- Dupilumab, Omalizumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
- Conditions
- Pouchitis
- Interventions
- CLF065, Placebo
- Drug
- Lead sponsor
- Calibr, a division of Scripps Research
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- La Jolla, California • Los Angeles, California • New York, New York
- Conditions
- Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
- Interventions
- 80 mg RPH-104, Placebo
- Biological · Drug
- Lead sponsor
- R-Pharm Overseas, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- Pasireotide (SOM230), placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Submental Fat
- Interventions
- 10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection
- Drug
- Lead sponsor
- 10xBio, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Encino, California • San Diego, California • Rolling Meadows, Illinois
- Conditions
- The Frailty Syndrome
- Interventions
- Ghrelin Group 1, Ghrelin Group 2
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastric Motility Disorder
- Interventions
- Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Uveitis
- Interventions
- Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 48 more
- Conditions
- Primary Mitochondrial Disease
- Interventions
- Elamipretide, Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more
- Conditions
- Systemic Sclerosis
- Interventions
- Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 51
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
- Conditions
- Hypochondroplasia
- Interventions
- Vosoritide, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 0 Months to 36 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 7 more
- Conditions
- Type 2 Diabetes
- Interventions
- LY2189102, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more
- Conditions
- Hemodialysis Complication, Hypotension of Hemodialysis
- Interventions
- Lanadelumab Injection [Takhzyro], Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
- Interventions
- Alirocumab, Placebo Matched to Alirocumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 11
- States / cities
- Mission Viejo, California • Newport Beach, California • Thousand Oaks, California + 8 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Rezpegaldesleukin, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Hyperglycemia
- Interventions
- pasireotide
- Drug
- Lead sponsor
- Robert R. Henry, MD
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Axial Spondyloarthrithis, Ankylosing Spondylitis
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
- Conditions
- Asthma
- Interventions
- Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 964 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more